CKRI
2021-07-29
Pls like
AstraZeneca exploring options for COVID-19 vaccine business, exec says
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":808138953,"tweetId":"808138953","gmtCreate":1627563875272,"gmtModify":1633763780329,"author":{"id":3578398190985905,"idStr":"3578398190985905","authorId":3578398190985905,"authorIdStr":"3578398190985905","name":"CKRI","avatar":"https://static.tigerbbs.com/46ea6437d16414ca8a956e66caf2c956","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/808138953","repostId":2155901652,"repostType":4,"repost":{"id":"2155901652","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627554420,"share":"https://www.laohu8.com/m/news/2155901652?lang=&edition=full","pubTime":"2021-07-29 18:27","market":"us","language":"en","title":"AstraZeneca exploring options for COVID-19 vaccine business, exec says","url":"https://stock-news.laohu8.com/highlight/detail?id=2155901652","media":"Reuters","summary":"LONDON, July 29 (Reuters) - AstraZeneca(AZN.L)is exploring options for the future of its COVID-19 va","content":"<p>LONDON, July 29 (Reuters) - AstraZeneca(AZN.L)is exploring options for the future of its COVID-19 vaccine business and expects greater clarity on the matter by the end of 2021, a senior executive told Reuters on Thursday.</p>\n<p>The comments are the first time the drugmaker has publicly confirmed that it is reviewing the future of the business after a series of setbacks in its race to develop a shot for the world.</p>\n<p>AstraZeneca agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.</p>\n<p>\"We are exploring different options,\" AstraZeneca Executive Vice President and President of the BioPharmaceuticals Business Unit Ruud Dobber said, referring to the vaccines business.</p>\n<p>\"Before year-end, we will have more clarity... if you ask me, is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion.\"</p>\n<p>Dobber said that AstraZeneca was committed to delivering a massive rollout of hundreds of millions of doses that were covered by current contracts.</p>\n<p>But he added that a \"small group of people reporting into Mene (Pangalos, research chief) and myself are thinking about (whether this is) a sustainable business.\"</p>\n<p>\"We need to have that discussion with our senior executive team, and then with the board of AstraZeneca,\" he said.</p>\n<p>\"We are exploring different options, but it is far too early at this stage to conclude that (process).\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca exploring options for COVID-19 vaccine business, exec says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca exploring options for COVID-19 vaccine business, exec says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-29 18:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, July 29 (Reuters) - AstraZeneca(AZN.L)is exploring options for the future of its COVID-19 vaccine business and expects greater clarity on the matter by the end of 2021, a senior executive told Reuters on Thursday.</p>\n<p>The comments are the first time the drugmaker has publicly confirmed that it is reviewing the future of the business after a series of setbacks in its race to develop a shot for the world.</p>\n<p>AstraZeneca agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.</p>\n<p>\"We are exploring different options,\" AstraZeneca Executive Vice President and President of the BioPharmaceuticals Business Unit Ruud Dobber said, referring to the vaccines business.</p>\n<p>\"Before year-end, we will have more clarity... if you ask me, is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion.\"</p>\n<p>Dobber said that AstraZeneca was committed to delivering a massive rollout of hundreds of millions of doses that were covered by current contracts.</p>\n<p>But he added that a \"small group of people reporting into Mene (Pangalos, research chief) and myself are thinking about (whether this is) a sustainable business.\"</p>\n<p>\"We need to have that discussion with our senior executive team, and then with the board of AstraZeneca,\" he said.</p>\n<p>\"We are exploring different options, but it is far too early at this stage to conclude that (process).\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155901652","content_text":"LONDON, July 29 (Reuters) - AstraZeneca(AZN.L)is exploring options for the future of its COVID-19 vaccine business and expects greater clarity on the matter by the end of 2021, a senior executive told Reuters on Thursday.\nThe comments are the first time the drugmaker has publicly confirmed that it is reviewing the future of the business after a series of setbacks in its race to develop a shot for the world.\nAstraZeneca agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.\n\"We are exploring different options,\" AstraZeneca Executive Vice President and President of the BioPharmaceuticals Business Unit Ruud Dobber said, referring to the vaccines business.\n\"Before year-end, we will have more clarity... if you ask me, is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion.\"\nDobber said that AstraZeneca was committed to delivering a massive rollout of hundreds of millions of doses that were covered by current contracts.\nBut he added that a \"small group of people reporting into Mene (Pangalos, research chief) and myself are thinking about (whether this is) a sustainable business.\"\n\"We need to have that discussion with our senior executive team, and then with the board of AstraZeneca,\" he said.\n\"We are exploring different options, but it is far too early at this stage to conclude that (process).\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":114,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/808138953"}
精彩评论